DICE Therapeutics, Inc.
NASDAQ: DICE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- J. Kevin Judice
- Employees
- 71
- Headquarters
- South San Francisco, United States
- IPO year
- 2021
- Market cap
- $2.3B
- Website
- https://www.dicemolecules.com
Loading DICE…
Loading profile data…Frequently asked questions about DICE
What does DICE Therapeutics, Inc. (DICE) do?
DICE Therapeutics, Inc. is a biopharmaceutical firm focused on creating innovative oral drug candidates to address chronic immunological disorders and other medical conditions. The company leverages its proprietary DELSCAPE platform, engineered to identify highly selective oral small molecules that can modulate protein-protein interactions (PPIs...
Where does DICE trade?
DICE Therapeutics, Inc. (DICE) trades on the NASDAQ Global Market.
What sector is DICE in?
DICE Therapeutics, Inc. (DICE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of DICE Therapeutics, Inc.?
J. Kevin Judice is the chief executive officer of DICE Therapeutics, Inc. (DICE).
Where is DICE Therapeutics, Inc. headquartered?
DICE Therapeutics, Inc. is headquartered in United States.
Does DICE pay a dividend?
DICE Therapeutics, Inc. (DICE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DICE go public?
DICE Therapeutics, Inc. (DICE) completed its initial public offering in 2021.